DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT04575194

UnknownPhase 4

Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

Cardiovascular and Metabolic Effects of Drugs for the Treatment of Obesity

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

40

estimated

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•Changes in blood pressure

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04575194
Org study IDObesity drugs study

Timeline

Milestones

Study start2020-09-08actual
Study first posted2020-10-05actual
Last update posted2020-10-08actual
Primary completion2022-09-30estimated
Study completion2023-05-30estimated

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Age ≥18 years with BMI ≥ 30 kg / m2 or BMI ≥ 27 kg / m2 in the presence of dyslipidemia or hypertension or obstructive sleep apnea or fatty infiltration or prediabetes.

Exclusion criteria

1. Presence of any clinical contraindications for the administration of liraglutide or bupropion / naltrexone

2. Bariatric surgery

3. Diabetes type 2

4. Active malignancy

5. Medication that affects weight (eg corticosteroids, phenothiazines)

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
4
Other (unclassified)
3
Cardiometabolic biomarkers
2
Glycemic / diabetes
1

Weight & body composition

4 endpoints
Secondary/protocol endpoint

Weight loss

Time frame:3 and 6 months

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Percentage of visceral fat

Time frame:3 and 6 months

Visceral fat, change

change from baseline, improvement

Secondary/protocol endpoint

Fat mass

Time frame:3 and 6 months

Total fat mass

change from baseline, improvement

Secondary/protocol endpoint

Fat free mass

Time frame:3 and 6 months

Lean mass

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Changes in glycemic

Time frame:3 and 6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Cardiometabolic biomarkers

2 endpoints
Primary/protocol endpoint

Changes in blood pressure

Time frame:3 and 6 months

change from baseline, improvement

Secondary/protocol endpoint

Changes in lipemic profile

Time frame:3 and 6 months

change from baseline, improvement

Other (unclassified)

3 endpoints
Secondary/protocol endpoint/low confidence

Autonomic nervous system function

Time frame:3 and 6 months

descriptive

Secondary/protocol endpoint/low confidence

Changes in meal induced thermogenesis

Time frame:3 and 6 months

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Changes in gut hormones involved in appetite regulation

Time frame:3 and 6 months

change from baseline, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.